Cysteinyl-Specialized pro-resolving mediators (SPMs) (Cysteinyl-SPMs) are a specialized subfamily of lipid mediators formed by enzymatic conjugation of Resolvins (particularly E-series) with cysteine-containing tripeptides (glutathione, cysteinylglycine, or cysteine alone). These hybrid molecules retain the pro-resolving bioactivity of their parent SPMs while gaining enhanced metabolic stability, altered receptor specificity, and additional signaling properties that bridge lipid and amino acid metabolism in inflammatory resolution.
Imagine a construction company's cleanup crew after demolishing a building (acute inflammation). The standard crew (regular SPMs) arrives with basic tools — they're effective but their equipment rusts quickly in the rain and they can only access certain locked areas. Now, someone at headquarters decides to upgrade: they coat the tools with a special rust-proof polymer (the cysteine-containing peptide) before sending the crew out. These upgraded tools (cysteinyl-SPMs) not only last longer in harsh conditions, but the polymer coating includes magnetic keys that open previously locked storage areas. The crew can now access more debris, work longer shifts without replacing equipment, and clear the site more thoroughly. The polymer coating doesn't change what the tools do fundamentally — they still clear debris and signal "all-clear" — but it makes them more durable and versatile. The raw materials for this polymer come from the company's recycling department (glutathione metabolism), linking the cleanup operation to the facility's antioxidant systems. If the recycling department runs low on polymer ingredients (glutathione depletion), the upgraded tools can't be manufactured, and cleanup becomes less efficient.
Cysteinyl-SPMs are biosynthesized through a multi-step enzymatic process that links omega-3 fatty acid metabolism with sulfur-containing amino acid pathways:
Biosynthesis Cascade:
Parent SPM formation: EPA or DHA undergo lipoxygenation by 15-LOX and 5-LOX to generate Resolvin E-series (RvE1, RvE2) or Resolvin D-series intermediates
Peptide conjugation: Glutathione-S-transferase (GST) enzymes catalyze nucleophilic attack by the thiol group of glutathione (γ-glutamyl-cysteinyl-glycine) onto the electrophilic carbon of the resolvin backbone, forming RvE-glutathionyl conjugates
Peptide trimming: γ-Glutamyltransferase (GGT) and dipeptidases sequentially cleave the γ-glutamyl and glycine residues, yielding RvE-cysteinyl or RvE-cysteinylglycine final products
Receptor engagement: Cysteinyl-SPMs signal through:
Downstream signaling:
Metabolic Stability Enhancement:
Functional Bioactivities:
Cysteinyl-SPMs represent a critical intersection between inflammatory resolution, antioxidant defense, and metabolic health, with direct relevance to multiple cPNI metamodels:
Metamodel 5 Integration (Organs as Selfish Systems):
The immune system's "selfish" resolution machinery requires adequate glutathione from hepatic and muscular stores. When chronic stress or oxidative stress depletes glutathione pools, cysteinyl-SPM biosynthesis fails despite adequate omega-3 substrate availability. This creates a resolution deficit — the immune system cannot properly terminate inflammation even when EPA/DHA intake is sufficient.
Clinical Conditions:
Chronic inflammatory diseases (IBD, rheumatoid arthritis): Patients often show low cysteinyl-SPM:parent-SPM ratios in plasma, indicating impaired conjugation capacity. Measuring RvE1-cysteinyl/RvE1 ratio provides functional assessment of glutathione-dependent resolution.
Glutathione depletion states: Acetaminophen toxicity, chronic alcohol use, sepsis, HIV infection — all impair cysteinyl-SPM production. Standard glutathione precursors (NAC, glycine, selenium) may restore cysteinyl-SPM synthesis when omega-3s alone fail.
Metabolic-inflammatory interface: Type 2 diabetes and NAFLD patients show reduced hepatic GST activity, limiting cysteinyl-SPM formation despite preserved 15-LOX/5-LOX function. This explains why omega-3 supplementation alone often shows modest benefits — the conjugation machinery is broken.
Intervention Implications:
Combined omega-3 + glutathione support: For resolution-resistant inflammation, provide both substrate (EPA/DHA 2-4 g/day) and conjugation capacity (NAC 600-1200 mg/day, glycine 3-5 g/day)
GST optimization: Cruciferous vegetables (sulforaphane) upregulate GST expression; consider if cysteinyl-SPM deficiency suspected
Biomarker monitoring: Emerging lipidomics panels can now measure cysteinyl-SPM levels; thresholds being established (preliminary data: RvE1-cysteinyl <0.5 ng/mL associated with prolonged resolution times)
Therapeutic window: Cysteinyl-SPMs show bioactivity at 1-100 nM in cell culture; translates to low nanogram/mL plasma concentrations clinically
Evolutionary Mismatch Context:
Hunter-gatherer diets provided abundant cysteine (meat), glycine (bone broth, connective tissue), and omega-3s (fish, wild game), supporting robust cysteinyl-SPM production. Modern diets high in processed foods provide inadequate resolution substrates on both fronts — creating a "resolution substrate mismatch" where inflammation initiates normally but cannot terminate efficiently.